Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

ClinicalTrials.gov ID: NCT01994382

Public ClinicalTrials.gov record NCT01994382. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin lymphoma.

Study identification

NCT ID: NCT01994382
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 260 participants

Conditions and interventions

Conditions

Interventions

Cerdulatinib Drug
Rituximab Biological

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 30, 2013 (Actual)
Primary completion: Dec 15, 2020 (Actual)
Completion: Dec 15, 2020 (Actual)
Last update posted: Apr 5, 2022

2013 – 2020

United States locations

U.S. sites: 23
U.S. states: 19
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Huntsville	Alabama	35805	—
Not listed	Gilbert	Arizona	85234	—
Not listed	Los Angeles	California	90095	—
Not listed	Palo Alto	California	94304	—
Not listed	Washington D.C.	District of Columbia	20007	—
Not listed	Gainesville	Florida	32608	—
Not listed	Sarasota	Florida	34232	—
Not listed	Lawrenceville	Georgia	30046	—
Not listed	Chicago	Illinois	60637	—
Not listed	Louisville	Kentucky	40207	—
Not listed	Baltimore	Maryland	21229	—
Not listed	Ann Arbor	Michigan	48109	—
Not listed	Hattiesburg	Mississippi	39402	—
Not listed	Hackensack	New Jersey	07601	—
Not listed	Morristown	New Jersey	07960	—
Not listed	New York	New York	10021	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Charleston	South Carolina	29412	—
Not listed	Arlington	Texas	76012	—
Not listed	Lubbock	Texas	79410	—
Not listed	Richmond	Virginia	23226	—
Not listed	Seattle	Washington	98109	—
Not listed	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01994382, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 5, 2022 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01994382 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →